"We believe we will offer in a year's time a complete cure for cancer", Aridor told the paper.
But Len Lichtenfeld, MD, chief medical officer of the ACS, said that "we must be aware that this is far from proven as an effective treatment for people with cancer, let alone a cure".
The treatment uses a combination of several cancer-targeting peptides for each cancer cell, reportedly eliminating the chance to be evaded by a mutation.
According to CBN News, the MuTaTo is also a "personalized drug" meaning that cancer patients simply submit a biopsy to the lab, allowing the team of expert scientists to analyze it and "give the patient a personalized cocktail of MuTaTo that will specifically destroy their particular cancer".
That translates to about 2.6 million fewer cancer deaths total than would have been expected if death rates stayed at their peak, which was seen in 1991, according to the study. For now, tests with mice in laboratories have been successful and it is estimated that within a year the application in humans will be developed.
"Our solution will be both generic and personal", Aridor stated.
Thurman: Lopez is like swiss cheese, he's got holes throughout
He weathered a storm in the middle rounds, with Lopez unleashing a fierce barrage in the seventh that had the champion in trouble. Lopez was able to withstand Thurman's best shots, but it wasn't enough to get the win on the cards.
Aridor and AEBi CEO Dr Ilan Morad insist that their treatment, named MuTaTo (multi-target toxin) is "essentially" a cancer anti-biotic - a disruption technology of the highest order.
Mutations in the targets - or downstream in their physiological pathways - could make the targets not relevant to the cancer nature of the cell, and hence the drug attacking it is rendered ineffective...
"The probability of having multiple mutations that would modify all targeted receptors simultaneously decreases dramatically with the number of targets used", Morad continued.
'We are living in an era where many exciting advances are impacting the care of patients with cancer.
"Instead of attacking receptors one at a time, we attack receptors three at a time, Morad told The Jerusalem Post".
The drug has not yet reached human trials, but the scientists say preclinical trials in mice have shown promising results. It was now on the cusp of beginning a round of clinical trials which could be completed within a few years and would then make the treatment available in specific case.